EmbectaEMBC
EMBC
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
78% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $1.39M
48% more capital invested
Capital invested by funds: $772M [Q3] → $1.14B (+$372M) [Q4]
0.36% more ownership
Funds ownership: 94.85% [Q3] → 95.21% (+0.36%) [Q4]
0% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 41
1% less funds holding
Funds holding: 358 [Q3] → 354 (-4) [Q4]
36% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 113
Research analyst outlook
We haven’t received any recent analyst ratings for EMBC.
Financial journalist opinion
Neutral
GlobeNewsWire
7 hours ago
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings.
Neutral
Seeking Alpha
1 month ago
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product.
Neutral
GlobeNewsWire
1 month ago
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference
PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET.
Neutral
Seeking Alpha
1 month ago
Embecta Corp. (EMBC) Q1 2025 Earnings Call Transcript
Embecta Corp. (NASDAQ:EMBC ) Q1 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - President & Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Ryan Schiller - Wolfe Research Operator Good day, and thank you for standing by. Welcome, ladies and gentlemen, to the Embecta Fiscal First Quarter 2025 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates
Embecta Corp. (EMBC) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.61 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025.
Neutral
GlobeNewsWire
2 months ago
embecta to Report Fiscal First Quarter 2025 Financial Results
PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025.
Neutral
Zacks Investment Research
2 months ago
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
Positive
Zacks Investment Research
2 months ago
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.
Charts implemented using Lightweight Charts™